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Heterogeneity and emergent behaviour in the vascular
endothelium
John G McCarron, Calum Wilson, Helen R Heathcote,
Xun Zhang, Charlotte Buckley and Matthew D Lee
The endothelium is the single layer of cells lining all blood vessels,
and it is a remarkable cardiovascular control centre. Each
endothelial cell has only a small number (on average six) of
interconnected neighbours. Yet this arrangement produces a
large repertoire of behaviours, capable of controlling numerous
cardiovascular functions in a flexible and dynamic way. The
endothelium regulates the delivery of nutrients and removal of
waste by regulating blood flow and vascular permeability. The
endothelium regulates blood clotting, responses to infection and
inflammation, the formation of new blood vessels, and
remodelling of the blood vessel wall. To carry out these roles, the
endothelium autonomously interprets a complex environment
crammed with signals from hormones, neurotransmitters,
pericytes, smooth muscle cells, various blood cells, viral or
bacterial infection and proinflammatory cytokines. It is generally
assumed that the endothelium responds to these instructions
with coordinated responses in a homogeneous population of
endothelial cells. Here, we highlight evidence that shows that
neighbouring endothelial cells are highly heterogeneous and
display different sensitivities to various activators. Cells with
various sensitivities process different extracellular signals into
distinct streams of information in parallel, like a vast switchboard.
Communication occurs among cells and new ‘emergent’ signals
are generated that are non-linear composites of the inputs.
Emergent signals cannot be predicted or deduced from the
properties of individual cells. Heterogeneity and emergent
behaviour bestow capabilities on the endothelial collective that
far exceed those of individual cells. The implications of
heterogeneity and emergent behaviour for understanding
vascular disease and drug discovery are discussed.
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Introduction
The endothelium regulates virtually every cardiovascular
activity by releasing numerous vasoactive agents. To
regulate blood flow and blood pressure, endothelium-
derived nitric oxide and prostacyclins promote vasodila-
tion, whereas production of endothelin, superoxide and
thromboxane stimulate vasoconstriction [1]. Blood fluid-
ity is regulated by endothelial factors that interrupt the
blood clotting cascade (antithrombin III, the protein C
receptor thrombomodulin, and tissue factor pathway
inhibitor [2]), platelet activation (nitric oxide and prosta-
cyclin, exonucleotidases and surface heparan sulphates
[2]) and fibrinolysis (tissue-type plasminogen activator
and its inhibitor plasminogen activator inhibitor-1 [3]).
Angiogenesis is regulated by the endothelium receiving
signals from molecules such as vascular endothelial
growth factor (VEGF) and von Willebrand factor [4–8].
Blood vessel permeability plays a key role in tissue
perfusion and host defence and is regulated by the
expression of endothelial cell adhesion molecules. Endo-
thelial cells also play a key role in immune and inflam-
matory reactions by regulating leukocyte movement into
tissues via production of chemokines, colony stimulating
factors and expression of specific proteins and cell adhe-
sion molecules at sites requiring defence or repair [9–11].
In making ‘decisions’ on vasoactive outputs, the endothe-
lium must coordinate responses across many cells to numer-
ous local and circulating cues. The cues are generated by
changes in physiological status and contained in signals
within the chemical environment to which the endothe-
lium is exposed. The environment is complex. Signals are
received in the form of the blood composition (e.g. pH, O2),
hormones, neurotransmitters, and from pericytes, smooth
muscle cells, various blood cells, viral or bacterial infection,
proinflammatory cytokines and even endothelial cells
themselves. Multiple signals may arrive simultaneously,
each providing separate instructions to the vascular system
[12–16]. To manage and accurately process the informa-
tion, the endothelium must selectively and sensitively
resolve each message held within the chemical environ-
ment while remaining resistant to the random spontaneous
activity in cells (noise).
Even a single message may itself vary widely in intensity
and carry different instructions at different concentra-
tions. Major physiological crisis events, such as bleeding,
may generate large local concentrations of activators [17]
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to evoke substantial immediate cardiovascular responses,
for example, blood clotting. However, a great deal of
cardiovascular activity is routine, small background
adjustments driven by modest changes in circulating
activators. Fluctuations in the concentration of agents
that activate the endothelium to produce background
physiological adjustments are vanishingly small and
require the endothelium to be exceptionally sensitive.
The concentration changes of circulating hormones, such
as leptin, estradiol, parathyroid hormone, epinephrine,
angiotensin II are small and vary periodically from a basal
value of a few tens of picomolar to a peak rise in the low
hundreds of picomolar [12–15,18]. Leptin, for example,
varies periodically over a 24 hour period from a basal
concentration of 49 pM to a peak of 99 pM (8–16 ng/
ml) [12]. Estradiol oscillates between 74 pM (20 pg/ml)
and 220 pM (60 pg/ml) though occasionally reached a
unusually high concentration of 1.5 nM (400 pg/ml)
[12]. Parathyroid hormone from 5 pM (50 ng/l) to 80 pM
(75 ng/l) [13] and epinephrine from 273 pM (50 pg/ml) to
2.2 nM (400 pg/ml) [19]. Even during a fight-or-flight
crisis epinephrine concentration may reach only
55 nM (10 ng/ml) [20]. Each of these concentrations
would be considered very low by conventional pharma-
cological standards. Yet the high-sensitivity enables the
endothelium to effectively monitor and respond to the
circulating activators to maintain ‘background’ cardiovas-
cular activity.
However, a problem coupled to the high-sensitivity of the
endothelium is how random ‘noise’ occurring in the
detection system can be rejected. Random noise is
unavoidable and arises from stochastic processes that
occur in the cells themselves. Random noise can evoke
signals of a substantial magnitude. The endothelium
must recognise these events as noise and prevent them
from evoking widespread activity while retaining high-
sensitivity. These features of endothelial sensitivity raise
a number of questions. How does the endothelium effi-
ciently detect exceptionally low concentrations of acti-
vators associated with background physiological events,
while also being able to respond to very high concentra-
tions during crisis (e.g. bleeding) events? How is noise
distinguished from ‘real’ signal? By what mechanism does
the endothelium process multiple, separate, and even
contradictory, messages? What underlies the change in
endothelial sensitivity that occurs in cardiovascular dis-
ease? The answers to these questions are largely
unknown but will provide fundamental insight into endo-
thelial function and the dysfunction occurring in cardio-
vascular disease.
In this review, we outline key properties of the endothe-
lium that are involved in the detection of the numerous
signals required for cardiovascular activity. We highlight
how the behaviour of individual endothelial cells differs
from expectations derived from the most common
experimental approaches used to study the endothelium
and the impact these differences may have on drug
discovery.
Uniformly heterogenous
Given the differences in haemodynamics, physiology and
structure of blood vessels, it is not surprising that endo-
thelial cell specialisation occurs in different parts of the
vascular system [21–33,34]. However, within a region of a
blood vessel, most studies examining sensing and activa-
tion treat the endothelium as a homogenous population of
cells that respond uniformly. Each cell, it is believed,
detects each signal equally, and each cell’s response is
considered to be a miniature version of the entire
response. An attractive feature of the proposal is that
no additional consideration is required to explain coordi-
nated function of the endothelium; coordination is
achieved by uniform activation of cells.
The hypothesis that endothelial cells behave uniformly is
implicit in most experimental approaches used to study
the endothelium. In organ bath experiments, the
mechanical response of the artery or vein is used as an
indirect measure of endothelial activity. This type of
experiment has yielded many important insights into
endothelial function (e.g. discovery of nitric oxide) but
averages the behaviour of thousands of endothelial cells
and assumes each cell behaves in a similar way. The organ
bath approach is not unique in assuming uniformity.
Many current interpretations of gene expression, protein
levels or metabolic signalling that are derived from immu-
noblots, PCR or microarrays also assume that all cells of a
population are comparable in receptor complement and
signalling processes [35,36]. When changes are reported
in cardiovascular disease, it is assumed all cells are altered
equally.
While the hypothesis of homogenous cell responses is
attractive and widely accepted, the hypothesis has not
been confirmed at the level of individual cells. When
individual cells in a population have been examined,
differences in the time course of responses or expression
of proteins have been almost universally reported
[37–40]. For example, signalling in cells occurs out of
phase with neighbouring regions and receptors are het-
erogeneously distributed [21,41–47]. The distribution of
angiotensin II immunostaining is irregular in neighbour-
ing endothelial cells of femoral mesenteric artery [30]. An
uneven mosaic pattern of von Willibrand factor (VWF)-
positive and von Willibrand factor (VWF)-negative endo-
thelial cells occurs in many vascular beds and even in
capillaries [30,48,49]. Adrenergic a-adrenoceptor clus-
ters and cannabinoid receptor distribution are heteroge-
neous among cells in the endothelium [42]. There is also
heterogeneity in the distribution of muscarinic (M3)
receptors and purinergic (P2Y2) receptors in neighbour-
ing cells (Figure 1; [50]).
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Functional data also show heterogeneity in endothelial
responses. Acetylcholine-evoked Ca2+ responses are
larger at branches in rat thoracic aorta than that of neigh-
bouring non-branch regions [51]. The reverse is true of
histamine [51]. Studies of murine thoracic aorta endo-
thelial cells that used only single concentrations of ago-
nists found that while most cells (82%) responded to
ATP, large fractions of cells did not respond to acetyl-
choline, bradykinin or substance P [52]. Responses to
mechanical activation also are not uniform and certain
populations of cells are more likely to respond to shear
stress [53].
Our results also demonstrate heterogeneity in the
endothelium’s response. Different cells respond to dif-
ferent concentrations of the activator acetylcholine [54].
As the concentration increased, an increasing number of
cells were recruited. The increasing recruitment of cells
was part of the concentration-dependence of the
response. While the sensitivity range of the endothelium
as a whole to acetylcholine extended over three orders of
concentration magnitude, each was sensitive over only
one order of magnitude [54], that is, the system has
properties that differ and exceed the properties of
individual parts (cells). This arrangement (having differ-
ent cells sensitive to various concentrations) solves a
problem common to sensory systems, that is, how to
create a system that is exceptionally sensitive to a stimu-
lus but does not saturate at low-stimulus intensity. The
endothelium’s organisation solves this problem by having
individual cells that are highly sensitive detectors of very
limited concentration ranges [54].
Interestingly, cells that were comparably sensitive were
positioned close together in discrete clusters. As the
concentration of each agonist increased, more cells in
the cluster activated and more clusters responded
[50,54]. These findings revealed that sensing cells are
neither randomly nor uniformly distributed, but struc-
tured into sensing regions [54].
The clustering of cells creates properties of the system
that are absent in single cells and generates a mechanism
to help reject noise. Clustering may provide a co-inci-
dence detection system [50,54]. When single cells in the
endothelium were activated (as would occur in stochastic
noise events), there is little propagation of signals
occurred to neighbouring cells. However, when two or
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Heterogenous distribution of muscarinic and purinergic receptors. (a) Fluorescence localisation of purinergic P2Y2 receptors and muscarinic M3
receptors in the endothelium. Representative images (from left) show the endothelial cell boundaries as revealed by PECAM-1 labelling (green;
anti-CD31/PECAM-1), P2Y2 receptor (red; anti-P2Y2) distribution, M3 receptor distribution (blue; fluorescent M3 receptor antagonist, 100 nM) and
overlay of all three. The receptors distribution was not uniform across the endothelium and there was relatively little overlap of purinergic and
muscarinic receptor staining. (b) Expanded view of the endothelial images shown in (a). The expanded region is shown by the red box in (a) left-
panel. All scale bars = 50 mm. Modified from Ref. [50] with permission.
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more neighbouring cells activated together, signal propa-
gation occurred. By rejecting noise, signal detection will
improve and randomly occurring events are unlikely to be
propagated. These observations again show that the
endothelium as a whole has properties that are quite
distinct from those of individual cells. Clustering may
offer other advantages. Clustering may allow the uptake
and breakdown mechanisms for diffusible messengers (e.
g. nitric oxide, prostaglandin) to be overwhelmed, pro-
viding increased spillover of signals. Clustering may also
limit interference from neighbouring cells that are
responding to a different stimulus, that is, a single cell
responding in isolation may easily be influenced by
neighbouring cells and have its signal overridden. A
cluster of cells each performing the same task may be
much harder to override.
The mechanisms giving rise to the organisation of cells
into clusters are not yet clear. Perhaps self-replication
occurs during development or the cells may be at differ-
ent developmental ages because of cellular renewal
. Alternatively there may be feedback control of function
and receptor expression based on location or a result of a
self-organisation process at the cellular level.
Fractured but whole; communication and
cooperation
While the system appears to be fractured and operating as
a series of distinct clusters of cells, communication
ensures the endothelium functions seamlessly as a har-
monised whole. Each endothelial cell is connected to
approximately six neighbouring cells (Figure 1; [50]) and
interaction occurs among connected cells. Communica-
tion via gap junctions [55,56] is an acknowledged feature
of the endothelium [55,57–59], and the low electrical
resistance (5–70 MV [60–64]) demonstrates the high
extent of connectivity among cells.
The communication pathways create a network capable
of relaying information [55,57–59,65]. However, the com-
munication pathways in the endothelium are usually
treated as being like a wire in a telecommunication
system. An input to the system is relayed from cell to
cell but decays passively with distance, as described by
the systems ‘cable properties’ [66]. The network itself is
not thought to interact with the input but relays signals
without changing the signals characteristics. In other
systems with similar passive network properties, separate
input signals may passively summate or cancel in an
approximately linear way. In this regard, the system
has linear features with ‘resultant’ properties which can
be predicted. The resultant may be a sum or a difference
of the interacting elements.
However, in contrast to the simple resultant properties of
a system, an incredible feature of the endothelium is that
the system may interact with the inputs to generate new
distinctive signals that differ in a non-linear way from the
inputs. The muscarinic agonist carbachol and purinergic
agonist ATP, activate spatially separate clusters of cells
[50]. In those separate clusters of cells, Ca2+ signals
evoked by carbachol and ATP are distinctive [50]. Car-
bachol evokes oscillating Ca2+ signals, ATP evokes an
initial Ca2+ spike followed by a decline towards basal
values (Figure 2). This observation demonstrates that an
input/output relationship exists for each agonist that is
temporally as well as spatially distinctive, that is, the
endothelium can distinguish inputs and assign outputs
(Figure 2).
While most endothelial cells are heterogeneous and par-
ticularly sensitive to one activator, a small number of cells
are sensitive to more than one activator [50]. When the
agonists are added separately, these cells also generated
distinctive signals to each agonist and the signals were
similar to those seen in cells sensitive to only one activator
(Figure 2; [50]). This observation suggests that the
distinctive signals evoked by each agonist are a feature
of the agonist acting on the cells rather than the cell itself.
Emergent signals. Surprisingly, even though separate cells
are activated by muscarinic and purinergic agonists, when
carbachol and ATP were present together, the resulting
Ca2+ signal is distinct from those signals generated by
either of the agonists in isolation (Figure 2; [50]).
The change in the response occurring, when both ago-
nists were present, is particularly interesting. The change
in the steady-state response is expansive in that it far
exceeds either the average or summation of the two
inputs (Figure 2; [50]). The generation of a distinct
new signal suggests that cells perform signalling compu-
tations and combine information from multiple sources.
The change in signal characteristics occur even though
distinct, separate cells were activated by each agonist,
that is, communication occurs between the separate clus-
ters (Figure 2; [50]). The computations on the signals
show the endothelium is flexible and interacts with the
inputs to generate new signals.
The precise nature of the computation carried out on the
signals and the underlying mechanisms are not clear.
Nonetheless, the computation is important in that it is
a feature that emerges from the collective dynamics of the
endothelial network and provides a mechanism for the
endothelium to interactively monitor external environ-
ments via distributed sensing across separate cells. Exam-
ining the endothelial system as a whole reveals properties
that are greater than the sum of its parts.
Emergent properties: why organise with
heterogeneity?
The interactive collective activity of the cells may hold
the key to resolving some of the incredible virtues of the
26 Cardiovascular and renal
Current Opinion in Pharmacology 2019, 45:23–32 www.sciencedirect.com
Interactive signalling in the endothelium McCarron et al. 27
Figure 2
CCh EC25 First Responding ATP EC25 First Responding Combined First Responding
CCh EC25
C
C
h 
EC
25
AT
P 
EC
25
C
om
bi
ne
d
C
C
h 
EC
25
AT
P 
EC
25
C
om
bi
ne
d
CCh
ATP
Combined
CCh
ATP
Combined
CCh
ATP
Combined
Summation
Mean
ATP EC25 Combined
Cell 1 Cell 2 Cell 3
0
.2
 F
/F
0 20 s
0
.2
 F
/F
0 20 s
P
e
a
k
 C
a
2
+
 R
e
s
p
o
n
s
e
(A
v
e
ra
g
e
 6
F
/F
0
)
A
v
e
ra
g
e
 C
a
2
+
 R
e
s
p
o
n
s
e
3
0
s
 a
ft
e
r 
in
it
ia
l 
P
e
a
k
 (
6F
/F
0
)
0.4
0.3
0.2
0.1
0.0
0.4
0.3
0.2
0.1
0.0
(d)
(c)
(b)
(a)
(e)
Current Opinion in Pharmacology
Unique signals in separate cells. (a) Composite Ca2+ images showing cells that respond in the first 4 s of activation by the EC25 concentrations of
CCh (left, green) and ATP (middle, red). Images are of the same field of endothelium. The right-panel shows cells activated (cyan) in the same field
of endothelium when both drugs were applied together. (b) Ca2+ responses from all activate cells in the field of endothelium shown in (a). The Ca2
+ increase evoked by CCh was (on average) a slow increase that remained elevated on which repeating oscillations occured (left green). The
response to ATP on average was a sharp transient increase that declined towards resting values (red middle). When both agonists were applied
(combined; blue right) the Ca2+ increase appeared to have features of each agonist, that is, a slow but larger initial increase than with CCh, which
remained more elevated than ATP and slowly declined. Agonists were present for the duration indicated by the line above each trace. (c)
Examples of responses from three separate cells to CCh, ATP and to the two agonists when applied together. In each panel in (c), traces are from
the cells indicated by the white dots in the panels in (a). It is the same three cells in each case. Cell 1 is shown in the left panel in (c), cell 2 in the
middle panel and cell 3 in the right panel. Cell 1 (left panel) responds to CCh but not to ATP. The characteristics of the response in Cell 1 is
altered when both ATP and CCh are present (combined) with a faster and larger upstroke. Cell 2 responds to ATP but not CCh. Once again, the
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endothelium (Figure 3). Endothelial heterogeneity per-
mits different cells to acquire, in an exceptionally sensi-
tive manner, different elements of the overall information
available. However, while cells detect a very limited
aspect of the total information content, information is
shared so that, collectively, the endothelium interprets
the entire chemical environment. As a collective, the
endothelium has properties that exceed the capabilities
of single cells. This feature is not unique to the endothe-
lium. Biological systems are recognised increasingly as
having properties that are distinct from the individual
components of the system. New distinct features often
arise from interactions and give rise to behaviours that are
absent when cells are examined in isolation.
New features that appear in a system and which differ
from the expectations of the sum of the components are
called ‘emergent properties’ [67,68]. Emergent properties
differ significantly from those observed in linear (resul-
tant) systems. Unlike linear systems where the whole is
equal to the sum of the parts, emergent systems arise from
non-linear interactions and create new collective beha-
viours that make the whole much greater than the sum of
the parts. Emergent properties cannot be reduced to
properties of the constituent parts of the system and
resist attempts at being inferred or predicted by calcula-
tion. In the case of the endothelium, distinctive signals
are generated to different agonists, and signals appear in
the system that are quite different from the sum of the
inputs when multiple agonists are present [50,54]. The
difference between the behaviour of individual cells and
the population average result in the endothelium as a
whole being capable of processing more information,
more precisely, than cells acting alone. These features
have important implications for basic investigations on
endothelial function and on drug discovery.
Emergent behaviour in cardiovascular disease. The underly-
ing rationale of most basic investigations is the desire to
understand the components that give rise to a response.
In disease, these components identify targetable pro-
cesses, for example, protein kinases, receptors or ion
channels, for small molecule design. Most drug discovery
investigations rely on averages from population (cells or
tissue) studies. However, this reliance assumes uniform
behaviour in populations, and believes an understanding
of how each cell works will results in an understanding of
the system, that is, the investigations are driven by
reductionism.
In the reductionist approach, a larger system is analysed
by breaking it down into pieces and determining the
connections between the parts [69]. Isolated cells, pro-
teins, molecules and ions have sufficient explanatory
power to provide an understanding of the whole system
and the changes that occur in disease (Figure 3). Reduc-
tionism has provided a wealth of knowledge on cellular
components and their function. However, despite the
success of reductionism, it is increasingly clear that bio-
logical function can only rarely be attributed to isolated
components.
Reductionist approaches have generated insights into
how cells work within a system; however, drug discovery
requires an understanding of how the overall system
works [70]. Yet, drug discovery is largely based on reduc-
tionist approaches such as genomics, proteomics, meta-
bolomics, high-throughput screening, combinatorial
chemistry and bioinformatics [70]. These approaches
have not brought the new products that were anticipated
[71,72]. For example, knowledge of the genome
sequences of humans and various pathogenic agents, once
hailed as the step change opening doors to new drug
development, and ‘personalised’ or ‘precision’ medicine,
has led to the identification of only a limited number of
beneficial drug targets [73]. Gene therapy, stem-cell
research, antisense technology and cancer vaccines have
not materialised to the degree so feverously predicted by
early supporters [72]. Despite eye-watering financial
investment, sixty years of reductionist approaches involv-
ing molecular targeting of drugs for specific enzymes and
receptors in cancer chemotherapies, have failure rates of
90% in those agents managing to reach end-stage trials
[74].
For cardiovascular drug discovery, an understanding of
the behaviour of the endothelium requires an apprecia-
tion of the multiple non-linear interactions and feedbacks
that occur within and among cells. The interactions and
feedbacks are currently poorly understood. Unfortu-
nately, even if a near complete understanding existed,
the behaviour of the system would remain difficult to
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(Figure 2 Legend Continued) characteristics of the response in Cell 2 is altered when both ATP and CCh are present (combined) with a more
sustained later Ca2+ change. Cell 3 responds to each agonist (CCh and to ATP). Once again, the characteristics of the response in Cell 3 is
altered when both ATP and CCh are present (combined). (d) Mean peak responses (black circles) to the EC25 of CCh and ATP separately and
when both were present together (combined). The red line shows the calculated mean of peak response when both agonists were added
separately. The red shaded region shows the standard error of the mean. The blue line shows the sum of the peak responses when both agonists
were added separately. The blue shaded region shows the standard error of the mean. The combined peak response exceeded the mean and
was less than the summed response. (e) Mean steady-state responses (black circles) to the EC25 of CCh and ATP separately and when both were
present together (combined). The red line shows the calculated mean of the steady-state response when both agonists were added separately.
The red shaded region shows the standard error of the mean. The blue line shows the sum of the steady-state responses when both agonists
were added separately. The blue shaded region shows the standard error of the mean. The combined steady-state response exceeded both the
mean and the summed response. All Scale bars = 50 mm. From Ref. [50] with permission.
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Figure 3
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Uniformity, heterogeneity and reductionism. (a) Illustration of a homogenous population of cells responding to single stimuli. Each cell responds
uniformly to either activator (green or red) and generates one output to each stimulus. (b) Heterogeneous populations of cells responding to one
(bi and ii) and two (biii) different stimuli. Separate spatially distinct clusters of cells process and respond to each activator to generate specific
outputs. When both activators are present together (biii) the separate regions respond and multiple outputs can be generated. This arrangement
permits the endothelium to simultaneously process different stimuli in parallel. (c) Illustration showing a reductionist approach to drug discovery.
The normal, steady-state behaviour present in health (ci) may be disrupted in disease (cii). The endothelium may compensate for this alteration by
upregulating proteins in other cells to restore a near normal steady-state in disease (ciii). A reductionist approach to drug discovery, that measures
the individual components, may attribute this upregulation to the dysfunction in disease rather than the compensatory mechanism employed by
the endothelium to overcome the disease. Targeting this upregulated protein may force the endothelium into another new steady-state that is not
beneficial (civ) which lacks the compensatory mechanism (cv) present before pharmacological intervention.
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predict and reconstruct. Altering the function of a com-
ponent in the system will have rippling unintentional
consequences, because of feedbacks and interactions,
that may be difficult to foresee and may rarely be benefi-
cial (Figure 3). Key to understanding the endothelium is
one defining principal – the endothelium exists in a
complex steady-state. The system resists changes and
will continuously work back (asymptotically) towards the
steady-state value.
In a cardiovascular disease, alterations of key components
(enzymes, ion channels) may trigger a change which
forces the entire system into a new steady-state, albeit
one that is dysfunctional. However, the new dysfunc-
tional condition will once again be maintained in a steady-
state by multiple altered interactions and feedbacks
occurring among enzymes, metabolic processes, ion chan-
nels and so on. As a result, there are multiple changes in
the function of the components of the system (e.g.
enzymes, ion channels). Most of the changes will be
consequences rather than causes of cardiovascular disease
and are, in fact, beneficial acting to stabilise the system
and halt or limit the progression of the disease (Figure 3).
The triggering, initiating, event may not be easy to
identify among the changes. Therefore, targeting path-
ways blindly, as is done through reductionism (e.g. iden-
tified with proteomics), may have adverse effects as
stabilising ‘beneficial’ changes will almost certainly be
targeted. It may be fruitless to attach any particular
significance to changes in specific biomarkers/proteins
(e.g. ion channels, enzymes) in cardiovascular disease
— they may be consequences rather than causes of the
disease. Pharmacologically altering the behaviour of a
biomarker/protein may not restore the system. Instead,
these pharmacological agents may cause additional
changes in overall function of the system and yet another
new steady-state could arise. The interactions and feed-
backs that occur in complex systems may explain why the
development of many, perhaps most, successful clinically
used drugs has been through serendipity rather than
rational drug design [75]. A successful approach for ratio-
nal therapeutic development in any system with emer-
gent properties will require an understanding of the
multiple interactions among vital components that sup-
port the entire network’s structure and function, and how
the interactions change in cardiovascular disease.
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